[Ip-health] Reminder: webinar tomorrow (Sept 26) - Is data exclusivity justified?: Evidence on the impacts on innovation and access to medicines

Marcela Vieira marcelacfvieira at gmail.com
Wed Sep 25 10:38:35 PDT 2019


Dear all,
Just a quick reminder that the webinar below is taking place tomorrow
(Thursday, September 26), at 4 pm CEST.

Is data exclusivity justified?: Evidence on the impacts on innovation and
access to medicines

Speakers:

Reed Beall, University of Calgary, Canada

Mayra Vásquez, National College of Pharmaceutical Chemists of Colombia

Miguel Cortés, UNOPS (United Nations Office for Project Services), Colombia

Host: Dr. Suerie Moon, Graduate Institute of Geneva

Thursday 26 September | 4:00pm-5:15pm CEST| 9:00am-10:15am COT|
8:00am-9:15am MDT

*To join the webinar, please register here:
https://www.knowledgeportalia.org/ <https://www.knowledgeportalia.org/>*

Kind regards,
---
Marcela Vieira
Researcher and Project Coordinator of the
Knowledge Network for Innovation and Access to Medicines
Global Health Centre, Research
Graduate Institute of International and Development Studies
marcela.vieira at graduateinstitute.ch

Em seg, 16 de set de 2019 às 09:14, Marcela Vieira <
marcelacfvieira at gmail.com> escreveu:

> Dear all,
>
> We are pleased to invite you to the next webinar organized by the
> Knowledge Network for Innovation and Access to Medicines, a project of the
> Global Health Centre at the Graduate Institute, Geneva.
>
>
> *Is data exclusivity justified?: Evidence on the impacts on innovation and
> access to medicines*
>
> *Thursday 26 September*
>
> *4:00pm-5:15pm CEST| 9:00am-10:15am COT| 8:00am-9:15am MDT*
>
> *To join the webinar, please register here
> <https://zoom.us/webinar/register/9615686180126/WN_JX034icVTdeaD7e25r4vsg>.*
>
>
>
> Speakers
>
>    -
>
>    Reed Beall, Assistant Professor, Cumming School of Medicine & O'Brien
>    Institute for Public Health, University of Calgary, Canada; Affiliated
>    Faculty, Program On Regulation, Therapeutics, And Law (PORTAL), Division of
>    Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham
>    and Women’s Hospital and Harvard Medical School, Boston, MA, USA
>    -
>
>    Mayra Vásquez, Pharmaceutical Chemistry, MSc Political Studies,
>    International Consultant in Pharmaceutical Policy and Medicines prices.
>    President National College of Pharmaceutical Chemists of Colombia, Regional
>    Cundinamarca, Secretary DURG-LA (Drug Utilization Research Group)
>    -
>
>    Miguel E Cortés G., Pharmaceutical Chemist; MSc Public health advisor,
>    Specialist in international drug price referencing, UNOPS (United Nations
>    Office for Project Services)
>
>
>
>  Research papers
>
> 1) Pre-market development times for biologic versus small-molecule drugs,
> 2019
>
>      https://rdcu.be/bHble
>
>
>
> 2) Impact of 10 Years of Data Exclusivity in Colombia, IFARMA, 2012
>
>     Full report in Spanish:
> http://www.ifarma.org/uploads/8/2/9/4/82946470/proteccion.pdf
>
>     Abstract in English: http://bit.ly/IFARMAdataexclusivity
>
>
>
> Background
>
>
>
> The information required to register a medicine may be the subject of an
> exclusivity period. This exclusivity period can delay the availability of
> generic medicines by impeding competition from other suppliers and thus,
> maintain high medicine prices. The length of exclusivity periods and the
> types of technologies covered vary among countries. Countries that do not
> provide this face constant pressure to do so during negotiations of trade
> agreements. What is the justification behind data exclusivity? And what are
> its impacts?
>
>
>
> Reed Beall will present a recently published study (above), which reviewed
> the pre-market development times for all new drugs approved in the United
> States over the past decade. The study concluded that there is no evidence
> showing that developing biologic drugs takes more time as compared to other
> drugs despite claims pushing for longer exclusivity periods for biologic
> drugs.
>
>
>
> The webinar also presents the Colombian experience in adopting data
> exclusivity for medicines in 2002. Mayra Vásquez and Miguel Cortés will
> present a study (above) that examined the impacts of data exclusivity 10
> years after its introduction in the country. The study observed that the
> data exclusivity period was responsible for an extra cost of US$ 412
> million in medicines expenditures. It also found that providing data
> exclusivity did not lead to faster entry of novel products in the Colombian
> market, which is another argument frequently used to justify the adoption
> of such provision.
>
>
>
> The webinar is free and open to the public and will be held in English.
> Participants will be able to pose questions orally or in writing, and the
> speakers will respond to a selection of these during the second half of the
> event. Recordings of all webinars will be made available at the
> <https://graduateinstitute.ch/research-centres/global-health-centre/knowledge-network-innovation-and-access-medicines>Knowledge
> Portal on Innovation and Access to Medicines
> <https://www.knowledgeportalia.org/webinars>. After registering, you will
> receive a confirmation email with additional information on how to join the
> webinar using the Zoom platform.
>
>
>
> We hope you will be able to join us for this informative discussion. This
> event is part of the webinar series of the Knowledge Network for Innovation
> and Access to Medicines, a project of the Global Health Centre at the
> Graduate Institute, Geneva. Suggestions for speakers and topics for future
> webinars are welcome at globalhealthresearch at graduateinstitute.ch.
>
>
> ---
> Marcela Vieira
> Researcher and Project Coordinator of the
> Knowledge Network for Innovation and Access to Medicines
> Global Health Centre, Research
> Graduate Institute of International and Development Studies
> marcela.vieira at graduateinstitute.ch
> http://www.graduateinstitute.ch/globalhealth
>


More information about the Ip-health mailing list